Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
Aventis Pharma (AVENTIS), previously known as Hoechst Marion Roussel (HMR), is a 50.1 % subsidiary of Aventis (formed by the merger of Hoechst AG and Rhone Poulenc). In 1999, the life sciences business of Hoechst AG and Rhone Poulenc SA were formally merged into a global life sciences giant called Aventis. The pharmaceutical business of both the companies has been combined into Aventis Pharma AG. The domestic product portfolio of Aventis Pharma includes 29 brands, 12 of which fall under the purview of the current DPCO. Some of its prominent brands include Cardace, Amaryl, Rabipur, Clexane, Lantus, ..etc.
Aventis focuses its activities on seven major therapeutic areas including cardiovascular diseases, thrombosis, oncology, central nervous system disorders, metabolic disorders, internal medicine and vaccines. With more than 99,000 employees in 100 countries across five continents, Sanofi-Aventis holds 5.3% of the global market share in healthcare. The company has Aventis Pharma Deutschland GmbH, Germany; PT Aventis Pharma, Indonesia; Aventis Pharmaceuticals Inc., USA; Aventis Pharma PTE, Singapore; Aventis Pharma, (U.K.) Investment et al as its subsidiaries. It holds 49% in its JV Chiron Behring Vaccines (CBVPL).
The company reported rise of 49.90% in standalone net profit on y-o-y basis to Rs 769.00 million, while total income increased 17.62% y-o-y basis to Rs 4.97 billion for the quarter ended September 2013.
Sanofi in India announced today that it has entered into a marketing and distribution agreement with Emcure Pharmaceuticals (Emcure) for its oncology portfolio in India. As per the agreement, while Sanofi will continue to own its oncology range - comprising 4 brands namely Taxotere??, Jevtana??, Fludara?? and Fasturtec??, Emcure will market and distribute these brands through its Specialty Unit.
Sanofi India, the leading pharmaceutical companies of the world, today announced the appointment of N Rajaram as country head and general manager, pharmaceutical operations, India with effect from April 2014. He reports to Shailesh Ayyangar, vice president, South Asia, Sanofi and managing director- Sanofi India.
Sanofi, the leading pharmaceutical companies of the world joined hands with PVR Nest (the social program and registered foundation of India`s largest film entertainment company PVR) for its `Healthy children, happy children` initiative to launch India`s largest student-led campaign on children`s health.
Sanofi, the International Diabetes Federation (IDF) and Public Health Foundation of India (PHFI) announced their first joint public health initiative in India, Kids (Kids and Diabetes in Schools).
Sanofi India, the pharmaceutical company announced today that it has signed an agreement with the wind turbine manufacturer, Suzlon Energy, for a 2.1 MW offsite windmall installation, to generate renewable power for captive consumption at its Ankleshwar manufacturing site.
Sanofi India, the leading pharmaceutical companies of the world, announced that a meeting of the board of directors of the company will be held on July 30, 2013.
Sanofi India announced that J. M. Gandhi, independent director of the company, who is a chartered accountant has informed the company that he would be retiring shortly as a partner of N. M. Raiji & Co. and after the said retirement he would be joining another reputed chartered accountants firm as a partner.
The Andhra Pradesh High Court (HC) on Friday ruled that Sanofi need not pay tax in India. Meanwhile, tax has to be paid for acquisiton of Shantha biotech.